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Abstract 
 
 
Parkinson Disease (PD), the most common movement disorder, is a 
neurodegenerative disease that affects about 1% of the human population over the age 
of 65 years, and its prevalence increases with age. PD is clinically characterized by 
resting tremor, rigidity and bradykinesia as a result of the loss of dopaminergic neurons 
in the substantia nigra pars compacta in the mid-brain. Mitochondria play a significant 
role in PD. The PD candidate gene VPS13C was identified in human using whole-
exome sequencing (WES). The VPS13C protein is involved in intracellular trafficking, 
especially lipid transportation, between the endoplasmic reticulum (ER) and other 
organelles, such as the late endosome/lysosome, as well as in the mitophagy pathway. 
I have successfully characterized the homologue of the human VPS13C gene in flies, 
Vps13. As a result, I have successfully modelled aspects of PD in Drosophila 
melanogaster. I found that inhibition of Vps13 improves the longevity and locomotor 
ability, while overexpression of Vps13 mostly reduced both the survival and locomotor 
abilities of flies. Furthermore, I have demonstrated that overexpression of Vps13 
significantly influences neurodevelopment when expressed in the developing 
Drosophila melanogaster eye. Our final set of experiments focused upon the 
consequences of the inhibition and overexpression of Vps13 when expressed with the 
co-inhibition of parkin, a well-known PD gene. These co-expressions can give valuable 
insights into the genetic and/or functional connections between the two genes or their 
protein products.  These findings suggest that the inhibition of parkin may improve the 
effects of Vps13 overexpression.  
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Introduction 
 
Purpose 
Parkinson disease (PD) is an age-dependent, neurodegenerative disease (NDD) that 
has incapacitating effects on the lives of patients. Due to the increasing age of 
populations within the next decade, research into PD has been receiving more attention 
than ever before. Despite the high prevalence of Parkinson disease, our knowledge 
about the influential factors and details about the disease are insufficient, and there is 
no absolute cure for it. The goal of this study is to characterize the Vps13 gene, a 
recently identified Parkinson disease candidate gene, and determine its influence on the 
survivorship and locomotory abilities of Drosophila melanogaster (D. melanogaster) 
as a model organism.  
 
 Parkinson Disease 
James Parkinson was the first medical scientist to describe Parkinson disease in 1817 
(Nussbaum et al., 1997). In the mid-1800s, Jean-Martin Charcot separated PD from 
multiple sclerosis (MS) and other diseases with tremor characterization (de Lau and 
Breteler, 2006). However, evidence suggests that this disease existed long before (Lysia 
S. Frono, 1996), as it was described in Leonardo Da Vinci’s transcripts sometime 
between 1489 and 1507, and Egyptian papyrus descriptions between 1350-1200BC. 
Parkinson clinical signs can be categorized into the motor and non-motor symptoms. 
Motor symptoms include impaired movement (bradykinesia), rigidity and resting 
tremor, or any combination of these, whereas non-motor symptoms consist of mood 
disorders and cognitive changes. Mood disorders may involve depression, anxiety, and 
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irritability, and cognitive changes may include problems with focused attention and 
planning, slowness of thinking, language and memory difficulties, personality changes, 
dementia, hallucinations and delusions, which leads to substantial disabilities and early 
death (Lysia S. Frono, 1996). Pathological symptoms are caused by the selective 
degeneration of the dopaminergic neurons in the substantia nigra pars compacta 
(SNPC) in the midbrain with the appearance of Lewy Bodies (Lesage et al., 2016). The 
term Lewy Body is associated with the abnormal aggregation of proteins (mostly α-
synuclein and ubiquitin along with other proteins in PD cases) inside nerve cells that 
forms fibrillar cytoplasmic inclusions. Commonly, it is believed that this accumulation 
of protein results in cytotoxicity. However, the development and appearance of Lewy 
bodies are not exclusive to PD, and some PD patients do not show this type of 
aggregation (Verstraeten, Theuns and Van Broeckhoven, 2015a). Variable levels of α-
synuclein accumulation have been observed in PD cases regarding their fundamental 
genetic defects.  
For the most part, patients with PD show a temporarily-positive response to a 
Levodopa drug treatment to relieve many of the symptoms; the efficiency may decrease, 
along with the development of various side effects in the long-term (Marsden and 
Parkes, 1977). Approximately 90% of PD cases are believed to be sporadic in nature, 
and factors such as environment, age, and sex or any combination may contribute to the 
causation of PD (de Lau and Breteler, 2006; Ammal Kaidery and Thomas, 2018). 
Recent analysis has shown that 0.57% of the population with the age of 50 years or 
more are affected by PD, and a clear prevalence of the disease rises with age (Koprich, 
Kalia and Brotchie, 2017). As such, the prevalence of PD has been reported to be 1% 
among 65-year-old people (Abeliovich and Gitler, 2016) and 4 to 5% among people 
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aged 85 years (Farrer, 2006). Males have been reported to be 50% more susceptible 
than females (Swerdlow et al., 2001; Farrer, 2006). However, there is no evidence 
supporting the sex-linked genetic variability of this observation. Rather it is suspected 
that environmental influences such as smoking rates, working in certain types of 
workplaces, including mines, and the protective effect of estrogen may play an essential 
role in a higher disease occurrence in males compared to females. In addition, there is 
possibility that geographical location may be an influential factor in the prevalence of 
PD (Farrer, 2006). A study showed that the prevalence of PD is lower in Asia in 
comparison with Europe, North America, and Australia (de Lau and Breteler, 2006). 
One study (Wang et al., 2016), suggested that none of the four candidate genes 
associated with PD (VPS13C, MIR4697, GCH1, and SIPA1L2)  were established to be 
a significant PD risk factor in the Chinese populations. 
Genetic mutations are believed to be responsible for a small portion of PD cases, yet 
the sporadic and familial forms of PD share most of the common clinical, pathological, 
and biochemical features (Ammal Kaidery and Thomas, 2018). Studies of the genetics 
of PD guided the discovery of the importance of some organelles in the pathways related 
to this disease. Mitochondria are one of the most critical organelles involved in cell 
health and, therefore, crucial to study when investigating Parkinson disease. 
 
Mitochondria and Parkinson disease 
Mitochondria are responsible for the oxidative respiration of the cell through the 
synthesis of adenosine triphosphate (ATP) in aerobic cells. The structure of the 
mitochondrion consists of  four main parts including 1) a matrix space that houses the 
enzymes of the citrate cycle and beta-oxidation; 2) an inner membrane responsible for 
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electron transport for production of ATP, the ATP synthase enzyme, and some carriers 
for particular metabolites; 3) a relatively permeable outer membrane; and 4) an 
intermembrane space. Each organelle has an independent small circular DNA which 
encodes a small fraction of the mitochondrial complements of biomolecules, including 
some of the subunits of the ATP synthase and the mitochondria’s ribosomal mRNAs. 
Cytosolic ribosomes are responsible for the synthesis of the rest of the mitochondrial 
peptides that will be imported, post-translationally, to the specific intramitochondrial 
sites (Sherratt, 1991). In this symbiotic relationship, the cell benefits from its 
“powerhouse,” mitochondria for oxidative respiration, while providing many of the 
essential proteins for the mitochondria’s proper function.   
Mitochondria act to establish the essential connections between organelles, both 
physically and functionally, which are crucial for controlling the homeostasis of cellular 
processes (Todkar, Chikhi and Germain, 2019). The ER-mitochondria contact sites play 
a role in regulating lipid transfer between the two organelles and in mitochondrial 
division (Daniele and Schiaffino, 2014). Morphologically, mitochondria undergo 
dynamic changes through the processes of continuous fusion and fission activities and 
maintain their morphology by creating a delicate balance between these opposing 
actions (Deng, Dodson, Huang, & Guo, 2008). PTEN-induced kinase 1(Pink1) and 
parkin are two nuclear-encoded examples of genes that control the maintenance and 
turnover of the mitochondria. Mutations in these genes can result in early-onset PD (B. 
Wang, Abraham, Gao, & Yang, 2016). Studies suggest that mutations in Pink1 and 
parkin may cause defects in mitochondrial dynamics, as a loss of function of Pink1 or 
parkin may be responsible for mitochondrial fission reduction and/or fusion increase in 
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the spermatids of D. melanogaster (Deng, Dodson, Huang, & Guo, 2008). Regulation 
of the dynamics of the mitochondria increases the longevity of cells. 
Mitophagy is an extremely important process, essential for the development of the 
organism, cell health, and the homeostasis of mitochondria, and is of paramount 
importance in the control of mitochondrial quality. During this fundamentally vital 
process, mitochondria are selected for disintegration, which occurs as a result of 
engulfment of damaged and/or excess mitochondria in a double-membrane 
autophagosome, and subsequent fission with either a vacuole or a lysosome for the 
purpose of degradation (Wang and Zhang, 2018). The Pink1/parkin associated 
mitophagy pathway (Michel, Hirsch and Hunot, 2016). Mitochondrial dysfunction, 
when coupled with disruption in the mitophagy process in SNPC, can lead to early-
onset PD (Lesage et al., 2016). Recently, autophagy and mitochondrial dynamics have 
been extensively studied in a select number of model organism systems. 
 
Modelling PD in Organisms 
Valuable insights into the basis of PD have been obtained through the exploitation 
of a number of excellent animal models. Techniques that have been used in animal 
models include toxin-based approaches, including the treatment of animals with 6-
hydroxydopamine (6-OHDA) (Breese et al., 2005) and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (T. Wichmann, 2009). Application of these techniques has 
been used to selectively destroy dopaminergic neurons in the brains of these animals to 
simulate phenotypes that attempt to mirror the symptoms of PD, to provide information 
regarding possible treatment approaches, and to investigate aspects of side effects 
related to such treatments. Although these toxin-based techniques may be fast and 
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informative, the  utility of such approaches can be questioned as the methods that are 
used for killing the dopaminergic neurons may produce a dopamine-loss phenotype, but 
may not necessarily reflect the nature by which the neurons degenerate during the 
development of PD (Koprich, Kalia and Brotchie, 2017). In contrast, genetic approaches 
to modelling PD have resulted in D. melanogaster becoming an invaluable model for 
studying such neurodegenerative diseases.  
 
D. melanogaster as a Model Organism 
D. melanogaster has been used as a model to study human disease for over a century, 
beginning with Thomas Hunt Morgan, the first geneticist to utilize the study of the fruit 
fly to investigate the genetics and the chromosomal theory of inheritance (St Johnston, 
2002; Pandey and Nichols, 2011). D. melanogaster has become an outstanding model 
organism for the genetic exploration of a wide variety of human diseases and the 
answering of an extensive range of biological questions. Although perhaps surprising 
to some, due to its very high level of functional conservation in many ways with 
vertebrates, the fruit fly can be used to further improve our knowledge of fundamental 
neurological disease mechanisms. Using D. melanogaster allows the determination of 
the possible effects of a given gene or genes through the suppression or enhancement 
of aspects of the disease model phenotypes since they can be examined through genetic 
modifier screening procedures or exploited to determine potential targets for therapeutic 
investigations. (Hewitt and Whitworth, 2017). Despite the significant difference 
between the anatomical arrangement of dopaminergic neurons in the D. melanogaster 
brain with the dopaminergic neurons in the vertebrate brain, a considerable level of 
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functional homology is shared (Strausfeld & Hirth, 2013) along with other advantages 
to be discussed. 
As an extremely well-studied genetic model organism, D. melanogaster was the first 
complex organism to have its whole genome sequenced. The genome, distributed 
among four chromosomes, codes for more than 14,000 genes (Pandey and Nichols, 
2011).  Once the human whole-genome was sequenced, it became clear that 75% of the 
genetic-based diseases in human beings have a functional orthologue in D. 
melanogaster (Lloyd and Taylor, 2010). The level of biological conservation and 
physiological positions similarity between flies and humans make the organism an 
extremely valuable tool for the study of human disease.  
Other advantages of using “the fly” as a model include: 1) they are relatively 
inexpensive; 2) their life cycle is fast; 3) they can produce over 100 genetically identical 
first-generation flies within 10 to 12 days in 25°C (Pandey and Nichols, 2011; Staveley, 
2012); and 4) their life span, which is usually around 70 days, makes  for easy study in 
laboratory settings. Importantly, the D. melanogaster brain structure is significantly 
complicated, with more than 100,000 neurons that mediate complex behaviours, such 
as feeding, memory, and flight navigation. Although perhaps somewhat counter-
intuitive to the uninitiated, D. melanogaster provides a system in which genetic 
characterization is relatively easy to accomplish and has the biological complexity to 
be compared in a very favourable way to the conditions of human disease. 
 
 
 
  
8 
 
UAS-Gal4 System 
Over the past few decades, many highly innovative methods have been developed to 
study the consequences of gene expression in cells and model organisms, especially  
D. melanogaster. The UAS-Gal4 system is a directed method of expression that allows 
the control of  expression of the desired gene temporally and spatially (Brand and 
Perrimon, 1993). The protein product of the Gal4 gene is a gene regulator and 
transcription factor, which was first identified in the yeast, Saccharomyces cerevisiae. 
The protein has a DNA-binding domain and a transcription activation domain at its N- 
and C-terminus, As a transcription factor, this regulator directly binds to a specific set 
of four related, seventeen base pairs (bp) sequences, known collectively as the Upstream 
Activating Sequence (UAS), which activates transcription from a basal promoter in the 
downstream location (Duffy, 2002). For the most part, Gal4 is naturally inactive in  
D. melanogaster, except for being the cause of cell death under some circumstances 
(Kramer and Staveley, 2003). The inability to induce gene expression in the absence of 
ectopic UAS sequences is critical in the workings of the UAS-Gal4 system as the gene 
located downstream of the UAS will not be transcribed unless the Gal4 protein is 
present. In order for the UAS-GAL4 method to be employed, the UAS must be situated 
in the upstream region of the desired gene in one of the parental lines and the Gal4 gene, 
directed by a tissue-specific promoter, must exist in the other parental line. With mating, 
these flies will then produce a critical class progeny that will have both Gal4 and UAS 
in their genomic complement; the GAL4 protein will then be able to bind to the UAS 
sites and activate the transcription of the gene at the time and in the specific cells or 
tissues for which the promoter specifies. Transgenes are put under the control of the 
UAS as this has the capability of expressing transgenes at significantly higher levels 
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than endogenous promoters (Carter, Shieh, Carter, & Shieh, 2015) (Figure 1). Critical 
class progeny are then able to be assessed for many phenotypes, including gross 
morphologies and locomotory and survivorship abilities. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
Figure 1. UAS-Gal4 system in Drosophila melanogaster 
After crossing transgenic group with responder group, the product of 
Gal4 gene (purple circles) attaches to the UAS which results in the 
expression of target gene (pink circles). 
Generated with draw.io. 
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RNA Interference and its function 
RNA interference (RNAi) is one of the cell’s natural ways to silence gene expression 
through degrading mRNA.  This can be utilized by cells in the regulation of gene 
expression or in protection, as it could degrade mRNA transcripts from viruses. This 
has become a powerful tool for scientists and enables them to selectively knockdown 
the expression of a gene by degrading the mRNA to a minimal level.  
In this system, double-stranded RNA (dsRNA) attaches to an enzyme called Dicer, 
which cleaves the dsRNA to fragments with 21-23 base pair lengths that are referred to 
as the small interfering RNA (siRNA). The dicer-siRNA complex attracts some other 
cellular proteins and forms an RNA-induced complex (RISC). This complex degrades 
mRNAs that are complementary to the siRNA sequence and therefore knocks down the 
production of a specific protein (Carter & Shieh, 2010). This inhibitory process can be 
coupled with the UAS-Gal4 system, which facilitates the knockdown of expression of 
a particular gene at a specific time and tissue. 
 
Genetics of Parkinson 
It was first believed that only sporadic agents were responsible for Parkinson disease 
and that no genetic factor was involved (Farrer, 2006); however, Nussbaum’s discovery 
in 1997 was a turning point in the treatments and understanding of Parkinson disease. 
They discovered that a missense mutation in the SNCA gene (encoding α-synuclein 
protein), located on locus PARK1/PARK4, could result in PD (Nussbaum et al., 1997; 
Houlden and Singleton, 2012). Since then, the tremendous work of researchers has 
revealed specific genetic agents responsible for Parkinson disease. For example, a 
number of dominant point-mutations in SNCA can result in familial early-onset 
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Parkinson disease; furthermore, the overproduction of the SNCA protein through 
duplicating and triplicating the SNCA gene, have shown a relation to familial early-
onset Parkinson disease (Khurana, Chung and Data, 2017). It has become clear that 
about 5-10% of the early onset PD cases are caused by genetic agents, and about 90% 
of the late-onset PDs are sporadic with no specific known causes (Abeliovich and Gitler, 
2016). I predict that this number will increase as we learn more about the genetics of 
Parkinson disease. 
PD is genetically very complicated, considering its numerous gene loci and the 
various disease risk factors (Verstraeten, Theuns and Van Broeckhoven, 2015b). 
Dysfunction in some cellular functions, such as vesicular trafficking, mitochondrial 
homeostasis, ER homeostasis, and Golgi homeostasis can lead to the sporadic and 
familial form of PD as well.  
To date, a minimum of 25 genetic risk factors, at least 20 distinct gene loci for familial 
PD  and  15 confirmed genes for the Mendelian forms of PD with an autosomal dominant 
or recessive form of inheritance have been confirmed (Verstraeten, Theuns and Van 
Broeckhoven, 2015b); such as ATPase Cation Transporting 13A2 ( ATP13A2), Familial 
Parkinson disease type 2 (PARK2), Parkinsonism associated deglycase (PARK7), 
Phosphatase tensin homologue [PTEN], induced kinase 1 (PINK1), in autosomal 
recessive form, α-synuclein (SNCA) and Leucine-rich repeat kinase 2 (LRRK2),in 
autosomal dominant form, and vacuolar protein sorting 35 (VPS35) F-Box protein 7 
(FBXO7), and RAB39B.  However, the occurrence of PD, with the involvement of 
multiple genetic and environmental factors, is more common than mendelian forms 
of parkinsonism (Satake et al., 2009). In 2017, using whole-exome sequencing (WES), 
27 new PD candidate genes were identified,  and VPS13C, UHRF1BP, ARSB, and 
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CAPS2, were some of those represented genes (Jansen et al., 2017). In the following 
paragraph, I will focus on Vps13C as the gene of interest.  
 
PARK23/VPS13C 
VPS13C, vacuolar sorting-associated 13 protein (Q709C8), also known as PARK23 
and KIAA1421, is localized on chromosome 15q22.2. It consists of 208kb of 
nucleotides, which includes 86 exons that encode 3753 amino acids (Lesage et al., 
2016). VPS13C is a member of the VPS13 gene family, which includes VPS13A 
(involved in chorea-acanthocytosis), VPS13B (involved in Cohen syndrome), VPS13C 
(involved in Parkinson’s Disease) and VPS13D (involved in altered IL-6 production) 
(Velayos-Baeza et al., 2004). Despite having the largest number of exons among all of 
the VPS13 family, VPS13C has the smallest genomic area and second smallest coding 
sequence.  
 Two main splice variants have been identified by Velayos and colleagues, variant 
1A, and variant 2A (Velayos-Baeza et al., 2004; Lesage et al., 2016). Variant 1A 
includes exons 1 to 5 and 8 to 85 (Skipping exon numbers 6 and7). It encodes a deduced 
3,710 amino acid protein, is expressed in all of its tested tissues, and shows relatively 
homogeneous patterns. On the other hand, variant 2A includes exons 1 to 85 (including 
exons number 6 and 7) which encode a deduced 3,753-amino acid protein expressed 
only in the brain, although at an equivalent or even higher level than variant 1A. Variant 
2A contains a lysine-rich domain encoded by exon number 7. 
Parkinson disease via VPS13C in humans can occur as a result of mutations in the 
VPS13 gene, which is responsible for both neurodevelopmental and neurodegenerative 
disorders. In 2017 through WES and Sanger sequencing, it was predicted that a mutation 
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in VPS13C on nucleotide number 62174851, which substitutes a Cytosine with 
Adenine, leads to a stop codon in that RNA sequence and consequently causes loss of 
function in recessive forms of PD. VPS13C is associated with Golgi to endosome 
transport such as vesicular transport and protein delivery to the lysosomes (Saxena et 
al., 2010), membrane traffic at the Golgi–endosome interface (De et al., 2017), and lipid 
transport between mitochondria and other organelles (Dimmer and Rapaport, 2017; 
Kumar et al., 2018), functional roles have been established in adipogenesis (Yang et al., 
2016) and early impairment of blood glucose homeostasis (Windholz J et al., 2011). 
Mutation in VPS13C was identified in gastric and colorectal cancers with unstable 
microsatellites. Furthermore, VPS13C is involved in mitochondrion organization, 
through negative regulation of parkin-mediated stimulation of mitophagy in response 
to mitochondrial depolarization (Lesage et al., 2016). The same study shows that 
knockdown of VPS13C results in the perinuclear redistribution of mitochondria and 
mitochondrial fragmentation.  
VPS13C is also associated with a decrease in mitochondrial transmembrane 
potential. VPS13C silencing enhanced pink1/parkin-mediated mitophagy in response to 
mitochondrial damage. It increases respiratory cell rates as a compensatory adaptation 
response to the decrease in the mitochondrial membrane potential. This phenomenon 
could be a result of the activation of the anti-apoptotic agent, B cell lymphoma 2 (Bcl2), 
that is located in the inner membrane of mitochondria that increase the mitochondrial 
membrane potential (Petit et al., 1995).  ATP production in neuronal cells is mainly 
through mitochondrial oxidative phosphorylation. In acute mitochondrial stress, these 
cells cannot switch to glycolysis (Lesage et al., 2016). These changes might, in the long 
term increase the production of  reactive oxygen species and cause irreversible damage 
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to mitochondria with severe consequences for the cell, including cell death. Cell death 
in substantia nigra pars compacta region can cause PD. 
PD-affected individuals with early-onset parkinsonism as a result of the loss of 
function in VPS13C initially show a positive response to levodopa treatment similar to 
PD-affected patients with mutations in their PARK2, PINK1,or DJ-1 (Lesage et al., 
2016). However, in affected individuals with VPS13C loss of function, motor 
dysfunction symptoms worsen faster, and levodopa treatments lose their efficiency 
more quickly. 
 
 The homologue Vps13 in D. melanogaster 
VPS13C in humans is a well-conserved homologue of Vps13 [FBgn0033194] in 
Drosophila, and to be more specific, Vps13 represents an orthologous form of the entire 
VPS13 family in humans (Thurmond et al., 2018). 
The Vps13 gene, with the annotation symbol of CG2093, is located on chromosome 
2R. It contains 13.87 kbp which starts from nucleotide number 7,566,809 to7,580,675. 
It has two annotated transcripts (Vps13-RA and Vps13-RB) and two polypeptide 
isoforms, meaning that both transcripts encode identical polypeptide sequences to each 
other. Vps13-RA has 10364 nucleotides that encode 3321 amino acids, and Vps13-RB 
owns 10480 nucleotides yet also encodes the same 3321 amino acids.  Its molecular 
function in D.melanogaster is still unknown, but it is involved in vacuolar protein 
targeting and protein metabolic process. It is associated with lysosomal degradation 
pathways, as well as having an important role in protein homeostasis maintenance in the 
brain of an adult Drosophila. Vps13 protein is a peripheral membrane protein that is 
located at the endosomal membrane. It is most abundant in the fly’s head.  Mutation in 
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Vps13 causes several abnormalities in flies, including shortening of fly’s life span and 
age-associated neurodegeneration. Furthermore, it creates sensitivity to proteotoxic 
stress and accumulated ubiquitylated proteins (Vonk et al., 2017); Vps13 mutants make 
good models for understanding the function of Vps13 in the brain.  
 
Goals and objectives  
 In this study, the genetics of PD is discussed with emphasis on specific gene 
VPS13C in humans and its homologue Vps13 in Drosophila melanogaster.  I have 
attempted to determine how inhibition and overexpression of Vps13 may simulate the 
neurodegenerative Parkinson disease in Drosophila melanogaster as a model organism. 
I used the alteration of pattern formation in the eye as an indicator of neurodevelopment 
disorders. The responsible gene in that experiment could be identified as a 
neurodegenerative agent. I have also assessed the impact of inhibition and 
overexpression of Vps13 in D. melanogaster’s survivorship and climbing abilities and 
so its relationship with PD. Furthermore, assessing the effect of inhibition and 
overexpression of Vps13 on inhibition of the parkin gene in D. melanogaster is of our 
interest 
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Materials and Methods 
Bioinformatics Analysis 
 
Identification of the Drosophila homologue of Vps13 from the human sequence 
The D. melanogaster homologue of Vps13 was identified using the National Centre 
for Biotechnology Information’s (NCBI) tBLASTn search tool 
(https://www.ncbi.nlm.nih.gov/). The D. melanogaster genomic sequences were searched 
using the amino acid sequence of the human Vacuolar protein sorting-associated protein 
13C (accession number Q709C8.1). Accession numbers were retrieved from NCBI to 
be used in the alignment. The D. melanogaster potential homologue was identified as 
Vps13 (accession number NP_610299.2). 
 
Identification of additional homologues, multiple alignments, and domain 
identification 
Homologues of D. melanogaster Vps13 were identified using the NCBI’s Basic 
Local Alignment Search Tool (BLAST) with the tBLASTn function 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=tblastn&PAGE_TYPE=BlastSearch&LI
NK_LOC=blasthome). The D. melanogaster Vps13 sequence was queried against the 
BLAST database. Sequences were aligned using Clustal Omega to show similarity 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). Domains were identified using Pfam (Sanger 
Institute) (https://pfam.xfam.org/search/sequence) and NCBI Conserved Domains 
Database (Figure:2) (https://www.ncbi.nlm.nih.gov/cdd). Clustal Omega was used to 
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create Percent Identity Matrix of protein sequences encoded by the Vps13 and VPS13C 
in all vertebrates and invertebrates used for the alignment and then was visualized using 
Python programming language version 3.7 (Figure:4). A phylogenetic tree was 
constructed using Clustal Omega (Figure:5) 
 The accession numbers for the alignment, including vertebrates and invertebrates, 
include D. melanogaster Vps13 protein (accession number NP_610299.2), Homo 
sapiens VPS13C protein (accession number Q709C8.1), Mus musculus VPS13C 
protein (accession number NP_796158.2). Gallus gallus VPS13C protein (accession 
number XP_001233000.2), Lucilia cuprina Vps13 (accession number 
XP_023292594.1), Culex quinquefasciatus Vps13 protein (accession number 
XP_001858599.1), and Anoplophora glabripennis Vps13 (accession number 
XP_018574731.1).  
 
D. melanogaster Culturing and Crosses 
D. melanogaster Media 
D, melanogaster stocks and crosses were maintained on a standard media 
containing 5.5 g/L agar, 65 g/L cornmeal, 15 g/L yeast, and 50 ml/L fancy grade 
molasses diluted in water with 5 ml of 0.1g/ml methylparaben in ethanol and 2.5 ml of 
propionic acid. Approximately 7 ml of medium were poured per vial. The medium was 
prepared by Dr. Brian E. Staveley about twice a month and stored at 4 to 6°C until use. 
 
D. melanogaster Stocks 
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All D. melanogaster stocks were ordered from the Bloomington D. melanogaster 
Stock Centre in Indiana University, IN, USA And Vienna D. melanogaster Resource 
Center (VDRC) 
The double-balancer complex line Ddc-GAL4-UAS; parkin RNAi was prepared by Dr. 
Brian E. Staveley (Table 1). 
Table 1. Genotypes of stocks used to characterize Vps13 in this study 
Genotype Abbreviation Expression 
Pattern 
Balance
r 
Provider Reference 
Transgenic Lines 
w;GMR-
GAL412 
GMR-Gal4 Eye … Bloomington 
Drosophila 
Stock Center 
(Freeman,19
96) 
w[*];P{w[+m
W.hs]=GawB}
D42 
D42-Gal4 Motor 
neuron 
specific 
… Bloomington 
Drosophila 
Stock Center 
Parkes et al., 
1998 
w1118;P{ddc
GAL4.L} 4.3D 
Ddc-Gal4 Neuron … Bloomington 
Drosophila 
Stock Center 
Li et al.,2000 
w*;P{ple-
GAL4.F}3 
Th-Gal4 Dopaminer
gic Neuron 
… Bloomington 
Drosophila 
Stock Center 
Inamdar et 
al., 2014 
UAS Lines 
w;UAS-lacZ 4-
1-2 
UAS-lacZ … … Bloomington 
Drosophila 
Stock Center 
Brand et al., 
1994 
y[1]sc[*]v[1];
P{y[+t7.7]v[+
t1.8]=TRiP.H
MS02460}attP
40 
UAS- Vps13-
RNAiHMS024
60 
… CyO Bloomington 
Drosophila 
Stock Center 
Perkins et al., 
2015 
y[1]sc[*]v[1];
P{y[+t7.7]v[+
t1.8]=TRiP.H
MS01715}attP
40 
UAS- Vps13-
RNAiHMS017
15 
… CyO Bloomington 
Drosophila 
Stock Center 
Perkins et al., 
2015,  
y[1]w[67c23];
P{w[+mC] 
y[+mDint2]=
EPgy2}EY096
40 
UAS- 
Vps13 
EY09640 
… … Bloomington 
Drosophila 
Stock Center 
Bellen et al., 
2004,  
w[1118]; 
P{GD14789}v
29972 
UAS- Vps13-
RNAiGD1478
9 
… … VDRC Dietzl et al., 
2007, 
 
UAS Complex Lines 
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w;ddcGAL4/C
yO;UASparkin
RNAi/TM3 
Ddc-
Gal4;UAS-
Parkin-RNAi 
Neuron CyO, 
TM3 
Staveley Lab M’Angale 
and Staveley, 
2016 
 
 
 
 
D. melanogaster crosses 
The stocks of all transgenic lines were maintained separately at room temperature 
(22°C±2), and the media refreshed every ten to fourteen days. Males from the desired 
inhibition or overexpression UAS lines were crossed with virgin females from lines that 
contained a GAL4 transgene. To collect virgin females for crosses, newly eclosed 
females were isolated every 8 to 12 hours (twice a day) from stock tubes and maintained 
upon fresh media in groups of 3 or 4 and left for 6 to 7 days for confirmation of their 
virginity. They were then mated with males of desired genotypes. To do so, 3 to 5 virgin 
females and 2 to 3 males of desired genotypes were combined and placed in fresh media 
for breeding. To increase the efficiency of their breeding, the parental flies were 
transferred onto new media three times at 2 to 3 day intervals prior to being discarded, 
and the male progeny of the critical class were collected once eclosed. Male progeny of 
the critical class were kept at 25℃.  In order to eliminate the collection of F2 male 
progeny with unwanted genotype, the progeny collection tubes were discarded after 18 
days.  
 
Biometric Analysis of the Compound Eye 
Eye analysis of D. melanogaster shows the effect of specific gene manipulation upon  
neurodevelopment, and is accomplished by a comparison of ommatidia and bristle 
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numbers of each critical class to the control group. To do so, each of the desired UAS 
lines were crossed with the GMR-GAL4 transgenic line, as described previously, and 
the critical class male progenies were collected and matured for 3 to 5 days in groups 
of no more than 20 on standard medium at 25°C. The flies were transferred into pre-
labelled 1.5 ml Eppendorf tubes in groups of 10, frozen and stored at a temperature of 
-80°C. Flies were thawed at room temperature and mounted upon aluminum stubs. Each 
stub was cleaned, polished and prepared with double-sided sticky tape for 
immobilization of the sample flies. Using tweezers, approximately 15 to 17 flies were 
fixed on each stub under stereoscope so that all flies were laid onto their right side, and 
their left eyes were facing upwards. The stubs with fixed flies were desiccated for at 
least 48 hours before imaging. Scanning electron micrographs were taken of each eye 
using the FEI Quanta 400 Scanning Electron Microscope. The images were then 
analyzed using the software program ImageJ (Schneider, Rasband and Eliceiri, 2012). 
A total number of ommatidia and bristles and the disrupted area were determined. These 
data were then analyzed using GraphPad Prism 8.1.1 (GraphPad Software Inc.), where 
the mean ± standard error of the mean was calculated. Unpaired t-tests were used to 
determine significance. Results were deemed statistically significant when p < 0.05. 
 
Behavioural assays 
 Longevity assay 
The analysis of D. melanogaster survivorship under near-optimal conditions was 
conducted to determine the effect of specific gene manipulation on the lifespan 
compared to a control group. To accomplish this experiment, the male progeny of each 
critical class was collected every day and maintained on fresh medium. To reduce the 
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adverse effects of overcrowding, groups of no more than 20 flies per vial were kept until 
a sample size of 300 to 350 individuals for each cross was reached. Critical classes were 
aged at 25°C. Every 48 hours, the number of dead flies in each tube was recorded and 
surviving flies were then transfered onto the new fresh nutrient medium: if no deaths 
were recorded, fresh media was provided every four days. Flies were considered dead 
when no movement was observed. Data were analyzed, and the graph was drawn using 
the software GraphPad Prism 8 (Graphpad Software Inc.) using the log-rank test with 
significance considered at p < 0.05. 
 
Climbing Assay 
The climbing analysis was used to determine the effect of specific gene manipulation 
on the locomotory ability of flies compared to a control group. To do so, I collected 
seventy critical-class male progeny from desired crosses as described before within a 
day or two. They were then kept in separate vials as groups of 10 at 25°C. These flies 
were transferred onto new medium two times per week. I started scoring their climbing 
ability one week after their eclosion and continued scoring their locomotory ability 
every seven days until either the number of flies diminished to less than 10 in total or if 
at least 50% of the flies showed loss of climbing ability in two consecutive climbing 
assays. The climbing ability of fifty flies per genotype was assessed in five groups of 
ten. Ten trials were conducted for each cohort of ten flies per genotype, which allowed 
a total of 500 trials per genotype per week. The flies were scored every seven days on 
their ability to climb inside a 30 cm glass tube with a 1.5 cm diameter that was marked 
with five 2 cm sections along a buffer zone, and the levels were scored from 1, which 
is the closest level to the buffer zone to 5, which is the height from the last mark on the 
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tube above. Flies were first tapped down and then were given ten seconds to climb; after 
that, a score was given to each fly in the tube-based upon the sections reached. The 
flies’ alignment was repeated ten times (trials) per climbing session. The climbing index 
was calculated using an equation: Climbing index = Σ nm/N. “n” indicates the number 
of flies at a specific level, “m” is the score of the level which is between 1 and 5 and 
“N” is the total number of flies climbed in that trial (Todd and Staveley, 2008). Data 
were then analyzed using the software GraphPad Prism 8.1.1 (GraphPad Software Inc.). 
A nonlinear regression curve was then used with a 95% confidence interval to interpret 
the graphs of the 5-climbing index as a function of time in days for each genotype. The 
slope for each graph represents the rate of decline in climbing ability, and the Y-
intercept represents the initial climbing ability, and both parameters are calculated for 
each curve using GraphPad Prism 8.1.1. (GraphPad Software Inc.). Slopes of the curves 
were compared using a 95% confidence interval. Curves with no overlap by the 95% 
confidence interval were considered significantly different. 
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Results 
Bioinformatic Analysis of Vps13  
Vps13 is highly conserved among multiple species  
A multiple sequence alignment (MSA) is the alignment of three or more biological 
sequences such as protein, DNA, or RNA. This analysis can be used to understand the 
molecular evolution and structural relationships between different sequences. An MSA 
may illustrate conserved sequences and domains as well as pointed, insertion, and 
deletion mutations. Differences or substitutions in a single amino acid in the multiple 
alignment sequences are shown as multiple characters in a single alignment column, 
and insertion/deletions are shown as hyphens in the sequences of the alignments 
(Lipman, Altschul and Kececioglut, 1989).  Clustal Omega is a bioinformatic tool that 
is based on the (C) or (C++) programming language. The goal is to create the best 
pairwise alignment with the highest score. Clustal Omega uses computational 
algorithms, statistical models, and the factor of time, to evaluate the similarity scores of 
the sequences and obtain the optimal pairwise alignment. The highest score would be 
allocated to the highest levels of similarity, and the score decreases as the level of 
similarity decreases, with penalties assigned for each gap (Sievers et al., 2011). Clustal 
Omega is a fast and promising tool for multiple sequence alignments.  Multiple 
alignments of vertebrates Homo sapiens VPS13C protein (accession number 
Q709C8.1), Mus musculus VPS13C protein (accession number NP_796158.2). Gallus 
gallus VPS13C protein (accession number XP_001233000.2) and invertebrates  Lucilia 
cuprina Vps13 (accession number XP_023292594.1), Culex quinquefasciatus Vps13 
protein (accession number XP_001858599.1), and Anoplophora glabripennis Vps13 
(accession number XP_018574731.1) was done. D. melanogaster and Homo sapiens 
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showed 32.31% similarity in the Vps13 protein sequence alignment. The information 
of these alignments was used for creating the percent identity matrix that helped 
visualize the percentage of similarities between all the species used in the protein 
alignment (Figure 2). Pfam software revealed the presence of detected domains 
including N-terminal region of Chorein (Chorein N) which is a leucine zipper domain 
(Mizuno et al., 2007; Lesage et al., 2016), Vacuolar-sorting associated protein 13 
(VPS13), three repeating coiled region of VPS13 (VPS13 mid rpt), SHR-binding 
domain (SHR-BD) which is present in VPS13 proteins. Vacuolar sorting-associated 13 
protein C-terminal (VPS13C) and Autophagy-related protein C-terminal domain (ATG 
C). Chorein N, VPS13, two VPS13 mid rpt, SHR-BD, and VPS13C domains were 
detected in the VPS13 protein of the invertebrates. It is essential to mention that Flybase 
identifies the VPS13 domain, starting at amino acid number 137 to amino acid number 
369, which is shown in red colour in the multiple alignments, as Vacuolar protein 
sorting-associated protein 13, second N-terminal domain (VPS13_N2). Although Pfam 
software did not identify the ATG C domain in insects, multiple alignments showed a 
very high level of preserved amino acids in that area compared to vertebrates, which 
can lead to the conclusion that the ATG C domain has been conserved in invertebrates 
(Figure 2). For validating this observation, I used MSA to align Chorein-N and ATG 
domain of Vps13 in the fruit fly with ATG2A protein in mammalian cells and results 
showed high levels of conservation (Figure 3).  Furthermore, Vps13 protein contains a 
DUF1162 domain with an unknown function (Velayos-Baeza et al., 2004; Lesage et 
al., 2016), which Pfam did not report. There are some differences between the amino 
acid sequences of vertebrates and invertebrates. One of the most significant differences 
is the absence of a second VPS13 middle repeating coiled region domain in the 
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invertebrates. Most of the domains are highly conserved. Since vertebrates have four 
different types of VPS13 in their genome, and D. melanogaster has only one kind of 
Vps13, it was essential to detect the VPS13C domain in their protein sequence. 
The phylogenetic tree visualizes the amount of genetic evolution and changes during  
time, and the numbers are representative of these changes. As shown on the tree, Homo 
sapiens (0.06607) and Mus musculus (0.684) had the lowest amount of genetic 
differences while D. melanogaster (0.22352), had a higher amount of genetic variation 
as the result of genetic evolution (Figure 5). 
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Figure 2: The Vps13 protein is highly conserved between vertebrates and 
invertebrates 
Clustal omega multiple alignment of Vps13 protein. High lighted are N-terminal 
region of Chorein (Chorein N) (Green), Vacuolar-sorting associated protein 13 (VPS13) 
(Red), Repeating coiled region of VPS13 (VPS13 mid rpt) (Blue), SHR-binding domain 
(SHR-BD)(Yellow), Vacuolar sorting-associated 13 protein C-terminal 
(VPS13C)(Purple) and Autophagy- related protein C-terminal domain (ATG C)( 
Orange). “*” indicates identical amino acids in all sequences in the alignment, “:” shows 
conserved substitutions, and “.” indicates semi-conserved substitutions. The numbers 
on the left side of each line represents the last amino acid number in the sequence in 
that row. The names of each species in the alignment are shown in brackets on the right 
side of the each line. Domains were obtained from Pfam. 
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Figure 3. Chorein-N and ATG-C domain are similar in ATG2A and VPS13C 
proteins. Image A includes the Chorein-N domain (Green box), Image B includes the 
crucial sequence (Dark blue line) in the upstream of ATG-C domain (Light blue 
box/line).Boxes represent shared domains and lines represent domains specific to ATG2A. 
Image C is a schematic illustration of represented domains. “*” indicates identical amino 
acids in all sequences in the alignment, “:” shows conserved substitutions, and “.” indicates 
semi-conserved substitutions. The numbers on the left side of each line represents the last 
amino acid number in the sequence in that row. The names of the proteins used for the 
alignment are shown on the right side of the each line. Multiple sequence alignment was 
generated with Clustal Omega. Domains were driven from Pfam. Image C was created 
with draw.io application. 
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Figure 4. Percent Identity Matrix shows high level of preservation on Vps13 
Protein among vertebrates and invertebrates. 
The number shown in each cell represents the identity percentage of Vps13 protein 
comparing two species from the alignment. The intensity of the blue colour in each cell 
visualizes the amount of sameness in a way that the higher the identity percentage 
between two species the more intense the blue colour is.  
 
Figure 5.  Phylogenetic tree shows a high level of evolutionary distance between 
H. sapiens VPS13C and D. melanogaster Vps13. 
The numbers shown on the right side of the cladogram indicate the distance values 
as the lengths of branches represent the genetic distance and the approximate time 
since the genetic divergence in the alignment. The phylogenetic tree and the numbers 
are produced as the output of the multiple sequence alignment which is used as an 
indication of the evolutionary distance between the sequences. 
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Eye Analysis 
Effect of inhibition and overexpression of Vps13 upon D. melanogaster 
ommatidia and bristle numbers 
The D. melanogaster compound eye consists of about 750 to 800 spherical-shape 
structures that form hexagonal arrays called ommatidia and hair-like structures called 
bristles that together create eye units. These units are arranged in a highly consistent 
pattern. The viability of D. melanogaster is not dependent on the presence or the 
functionality of the eye, and genetic changes during the neurodevelopment could be 
easily detected and therefore analyzed. One can use the eye as an ideal model for 
understanding the genetics of neurodegeneration and neurodevelopment. The 
phenotypic alterations in the eye are mostly in shape, size, or arrangement of the units 
(Mishra M., 2012). In this study, I used GMR-GAL4 to control the inhibition and 
overexpression of Vps13 in the developing eye (Figure:6). Then, I counted the number 
of ommatidia and bristles of each compound eye using ImageJ software. Through 
observation, it became clear that in specific genotypes, there were significant areas that 
lacked bristles. To quantify this, I compared the area of the eye voided bristles to the 
total eye area and analyzed them through GraphPad Prism.  
 
Analysis of Ommatidia Number 
Ommatidia numbers were significantly decreased in the inhibited critical class GMR-
Gal4; UAS-Vps13-RNAiHMS01715 with the average ommatidia number of 679.8 ±17.92 
and the inhibited class GMR-Gal4; UAS-Vps13-RNAiHMS024460  with the average 
ommatidia number of 734.6 ±8.806 compared to the control group GMR-Gal4; UAS-
lacZ with the average number of 758. While the inhibition group GMR-Gal4; UAS-
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Vps13-RNAiGD14789, with the mean ommatidia number of 746.4 ±9.667, and 
overexpression GMR-Gal4; UAS-Vps13EY09640, with the average ommatidia number of 
768.2 ±9.253, did not show any significant changes compared to the control. N-value 
for all critical classes were 10 and p< 0.05 considered significant (Figure 7, Table 2). 
 
 Analysis of bristle number 
Bristle numbers in the inhibited group GMR-Gal4; UAS-Vps13-RNAiHMS01715 with a 
mean of 569.7 ±14.87 were significantly lower than the control group GMR-Gal4; UAS-
Vps13-lacZ while bristle numbers in the inhibited group GMR-Gal4; UAS-Vps13-
RNAiIHMS024460 flies with 644.6 ±20.12, and inhibited group GMR-Gal4; UAS-Vps13-
RNAiGD14789 with a mean of 634.3 ±6.340, were significantly higher than the control 
GMR-Gal4; UAS-lacZ . Overexpression group GMR-Gal4;UAS-Vps13EY09640, with an 
average bristle number of 510.2 ±6.740, showed a significant decrease in bristle 
numbers compared to GMR-Gal4; UAS-lacZ,  N-value for all critical classes were 10 
and p<0.05 considered significant (Figure 8, Table 2).  
 
Analysis of Bristle Void Area  
The percent of bristle void area was significantly decreased in all of the inhibited 
flies GMR-Gal4;UAS-Vps13-RNAiHMS01715, GMR-Gal4;UAS-Vps13-RNAiHMS024460 and, 
GMR-Gal4; UAS-Vps13-RNAiGD14789 and significantly increased in the overexpression 
group GMR-Gal4; UAS-Vps13EY09640 compared to the control. The percent of bristle 
void area in all critical class groups is as follows: The control line, GMR-Gal4; UAS-
lacZ ,14.10%, inhibition group GMR-Gal4; UAS-Vps13-RNAiHMS01715, 8.549 ±0.5537%, 
GMR-Gal4;UAS-Vps13-RNAiHMS024460, 8.607 ±0.3821% and, GMR-Gal4;UAS-Vps13-
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RNAiGD14789, 8.252 ±0.5113% and, overexpression line GMR-Gal4;UAS-Vps13EY09640, 
33.33 ±1.924%. N value for all lines was 10, and p< 0.05 considered significant. (Figure 
9, Table 2) 
 
 
 
 
Figure 6. Bristle numbers are reduced by the overexpression of Vps13 under 
control of eye-specific drivers in D. melanogaster compound eye. 
 
Images were taken in 450X magnification using the FEI Quanta 400 Scanning 
Electron Microscope. Each image relates to one of the experimented lines as follows: 
A-GMR-Gal4;UAS-lacZ, B- GMR-Gal4;UAS-Vps13-RNAiHMS01715, C- GMR-
Gal4;UAS-Vps13-RNAiHMS024460, D- GMR-Gal4;UAS-Vps13-RNAiGD14789, and E- 
GMR-Gal4;UAS-Vps13EY09640 
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Figure 7: Inhibition and overexpression of Vps13 under the influence of eye 
specific expression in most cases does not affect ommatidia numbers in D. 
melanogaster compound eye. 
N-value is 10, p<0.05 considered significant. Inhibition groups that are shown with 
green and blue colour (GMR-Gal4;UAS-Vps13-RNAiHMS01715and GMR-Gal4;UAS-
Vps13-RNAiHMS024460) showed significant decrease in their ommatidia number while 
inhibition group with purple colour (GMR-Gal4;UAS-Vps13-RNAiGD14789) and the 
overexpression group with red colour (GMR-Gal4;UAS-Vps13EY09640) had no 
significant differences with control group. 
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Figure 8. Overexpression of Vps13 under the influence of eye-specific expression 
reduces the bristle numbers while inhibition of Vps13 has the opposite effect on 
D. melanogaster compound eye 
N-value is 10, p<0.05 considered significant. Overexpression group GMR-
Gal4;UAS-Vps13EY09640  shows specific decrease in their bristle numbers while 
inhibition groups GMR-Gal4;UAS-Vps13-RNAiGD14789 and GMR-Gal4;UAS-Vps13-
RNAiHMS02460  show increase in their bristle numbers compared to control. 
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Figure 9. Overexpression of Vps13 under the influence of eye specific expression 
significantly decreases the bristle-void area in D. melanogaster compound eye. 
N-value is 10, p<0.05 considered significant. Overexpression of the Vps13 in the 
eye (GMR-Gal4;UAS-Vps13EY09640)  significantly increases the bristle void area while 
inhibition of Vps13 (GMR-Gal4;UAS-Vps13-RNAiHMS01715, GMR-Gal4;UAS-Vps13-
RNAiGD14789 and GMR-Gal4;UAS-Vps13-RNAiHMS02460) improved the bristle numbers 
in the eye compared to the control. 
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Table 2. Summary of unpaired t-test results for ommatidia number, bristle 
number and the percent bristle void area for inhibition and overexpression of 
Vps13 in D. melanogaster eye. 
 
 
 
 
 
 
Significant 
compared to control 
P-value Mean ± 
SEM 
Sample 
Size 
Genotype 
Ommatidia 
N/A N/A 758.1 10 GMR-Gal4;UAS-
Vps13-lacZ 
Yes 0.0004 679.8 
±17.92 
10 GMR-Gal4;UAS- 
HMS01715RNAi-13psV 
Yes 0.0157 734.6 
±8.806 
10 GMR-Gal4;UAS- 
HMS02460RNAi-13psV 
No 0.2418 746.4 
±9.667 
10 GMR-Gal4;UAS- 
GD14789RNAi-13psV 
No 0.2895 768.2 
±9.253 
10 GMR-Gal4;UAS-
EY09640 13psV 
Bristle 
N/A N/A 619.8 10 GMR-Gal4;UAS-
lacZ 
Yes 0.0036 569.7 
±14.87 
10 GMR-Gal4;UAS- 
5HMS0171RNAi-13psV 
Yes 0.0004 644.6 
±20.12 
10 GMR-Gal4;UAS- 
HMS02460RNAi-13psV 
Yes 0.0345 634.3 
±6.340 
10 GMR-Gal4;UAS- 
GD14789RNAi-13psV 
Yes 0.0001< 510.2 
±6.740 
10 GMR-Gal4;UAS-
EY0964013psV 
Percent Bristle Void Area 
N/A N/A 14.10 % 10 GMR-Gal4;UAS-
lacZ 
Yes 0.0001< 8.549 
±0.5537 % 
10 GMR-Gal4;UAS- 
HMS01715RNAi-13psV 
Yes 0.0001< 8.607 
±0.3821% 
10 GMR-Gal4;UAS- 
HMS02460RNAi-13psV 
Yes 0.0001< 8.252 
±0.5113% 
10 GMR-Gal4;UAS- 
GD14789RNAi-13psV 
Yes 0.0001< 33.33 
±1.924% 
10 GMR-Gal4;UAS-
EY0964013psV 
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Behavioural Analysis 
Directed dopaminergic neuron-specific expression 
 Longevity Assay 
I compared the longevity of each of the critical classes with the control group Th-
Gal4; UAS-lacZ using Log-rank statistical analysis. P<0.05 considered significant 
(Figure 10, Table 3). The control group Th-Gal4; UAS-lacZ has the N-value of 320 and 
the median life span of 64 days. Inhibition group Th-Gal4; UAS-Vps13-RNAiHMS01715 
with the N-value of 302 and median life span 58 days, inhibition group Th-Gal4; UAS-
Vps13-RNAiHMS024460 with the N-value of 271 and median life span of 58, and 
overexpression line Th-Gal4; UAS-Vps13EY09640 with the N-value of 308 and median 
life span of 46 days showed a specific decrease in their longevity. It is noteworthy that 
the reduction in the survivorship ability of the overexpression line Th-Gal4; UAS-
Vps13EY09640 was much more significant than the other mentioned inhibition groups. 
Surprisingly, inhibition group Th-Gal4; UAS-Vps13-RNAiGD14789, with the N-value of 
318 and median survival days of 72 days, showed a significant increase in its longevity. 
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Survivorship Analysis 
Genotype Number of 
Flies 
Median 
Survival 
(Days) 
Chi-
square 
Value 
P-value Significance 
Th-Gal4;UAS-
lacZ 
320 64 N/A N/A N/A 
Th-Gal4;UAS-
Vps13-
RNAiHMS01715 
302 58 89.38 <0.0001 Yes 
Th-Gal4;UAS-
Vps13-
RNAiHMS02460 
271 58 7.479 0.006243 Yes 
Th-Gal4;UAS-
Vps13-
RNAiGD14789 
318 72 173.4 <0.000001 Yes 
Th-Gal4;UAS-
Vps13EY09640 
308 46 299.7 <0.000001 Yes 
Table 3. Log-rank statistical analysis of longevity of flies with directed 
dopaminergic neuron-specific expression with inhibition and overexpression of 
Vps13. 
Figure 10. Overexpression of Vps13 under the control of directed dopaminergic 
neuron- specific expression decreases the longevity of D. melanogaster. 
P<0.05 considered significant. The error bars are made with a CI 95%. Inhibition 
group Th-Gal4; UAS-Vps13-RNAiGD14789 has the highest longevity while the 
overexpression group (Th-Gal4; UAS-Vps13EY09640) shown with red colour showed the 
lowest longevity 
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Climbing Assay 
I compared the locomotor ability of each critical class with the control group using 
non-linear regression analysis. N-value for every critical class group is 50, P<0.05 
considered significant (Figure 11, Table 4). All of the critical classes started with the 
same quality of climbing. Meanwhile, inhibition group Th-Gal4; UAS-Vps13-
RNAiGD14789 had an improved climbing ability over time compared to control Th-Gal4; 
UAS-lacZ throughout the whole experiment. However, although inhibition group Th-
Gal4; UAS-Vps13-RNAiHMS01715 had better climbing scores until day 35 (week five), its 
scores decreased significantly thereafter. Inhibition group Th-Gal4; UAS-Vps13-
RNAiHMS024460 showed no statistically difference with control Th-Gal4; UAS-lacZ, and 
Overexpression group Th-Gal4; UAS-Vps13EY09640 which notably showed reduced 
longevity, had a significant decrease in its locomotor ability. 
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Climbing Analysis 
Genotype Slope (k) SE 95% 
Confidence 
interval (CI) 
P-value Significance 
Th-Gal4;UAS-lacZ 0.05122 0.005
6 
0.04140 to 
0.06240 
N/A N/A 
Th-Gal4;UAS-Vps13-
RNAiHMS01715 
0.07585 0.004
8 
0.06601 to 
0.08712 
 
0.0001 Yes 
Th-Gal4;UAS-Vps13-
RNAiHMS02460 
0.05214 
 
0.003
9 
0.04486 to 
0.06019 
 
0.7957 No 
Th-Gal4;UAS-Vps13-
RNAGD14789 
0.06868 
 
0.005
8 
0.05712 to 
0.08214 
 
0.0434 
 
Yes 
Th-Gal4;UAS-
Vps13EY09640 
0.05545 
 
0.004
4 
0.04701 to 
0.06498 
<0.000
1 
Yes 
Figure 11. Overexpression of Vps13 under the control of directed dopaminergic 
neuron- specific expression decreases the climbing ability of D. melanogaster 
while inhibition of Vps13 increases it. 
 p<0.05 considered significant. The error bars are made a with CI 95%. 
 
 
 
 
 
Table 4. Statistical analysis of the locomotor ability of Drosophila melanogaster 
using non-linear regression curve with directed dopaminergic neuron-specific 
expression with inhibition and overexpression of Vps13. 
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Directed motorneuron-specific expression 
 
Longevity Assay 
I compared the longevity of each of the critical classes with the control group using 
Log-rank statistical analysis. P<0.05 considered significant (Figure 12, Table 5). The 
control group D42-Gal4; UAS-lacZ has the N-value of 280 and the median life span of 
57 days. Inhibition group D42-Gal4; UAS-Vps13-RNAiHMS01715 with the N-value of 328 
and median life span 40 days had a significant decrease in its longevity. While inhibition 
group D42-Gal4; UAS-Vps13-RNAiHMS024460 with the N-value of 276 and a median life 
span of 58 showed no significant differences with control D42-Gal4; UAS-lacZ. On the 
other hand, inhibition group D42-Gal4; UAS-Vps13-RNAiGD14789 showed a significant 
increase compared to control D42-Gal4; UAS-lacZ. No observation of substantial 
differences in inhibition group D42-Gal4; UAS-Vps13-RNAiHMS024460 and the 
improvement of the longevity in the inhibition group D42-Gal4; UAS-Vps13-
RNAiGD14789 could also be seen in the directed dopaminergic neuron-specific expression 
groups. However, unlike the directed dopaminergic neuron-specific overexpression 
group D42-Gal4; UAS-Vps13EY09640 with the N-value of 315 and a median life span of 
62 days showed a significant increase in their longevity 
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Table 5. Log-rank statistical analysis of longevity of flies with directed 
motorneuron-specific expression with inhibition and overexpression of Vps13. 
Survivorship Analysis 
Genotype Number of 
Flies 
Median 
Survival 
(Days) 
Chi-square 
Value 
P-value Significance 
D42-Gal4;UAS-
lacZ 
280 57 N/A N/A N/A 
D42-Gal4;UAS-
Vps13-
RNAiHMS01715 
328 40 418.0 <0.0001 Yes 
D42-Gal4;UAS-
Vps13-
RNAiHMS02460 
276 58 0.5337 0.4650 
 
No 
D42-Gal4;UAS-
Vps13-
RNAiGD14789 
315 68 227.9 
 
<0.0001 Yes 
D42-Gal4; UAS-
Vps13EY09640 
315 62 60.21 
 
<0.0001 Yes 
  
Figure 12. Inhibition and overexpression of Vps13 under the control of 
directed motorneuron-specific expression increases D. melanogaster 
longevity while decreases longevity of D42-Gal4; UAS-Vps13-RNAiHMS01715 
P<0.05 considered significant. The error bars are made with a CI 95%. 
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Climbing Assay 
I compared the locomotor ability of each critical class group with the control group 
D42-Gal4; UAS-lacZ using non-linear regression analysis. N-value for every critical 
class is 50, P<0.05 considered significant (Figure 13, Table 6). Overexpression line 
D42-Gal4; UAS-Vps13EY09640 started with lower climbing scores in the first climbing 
attempt compared to other critical class groups. Overexpression line D42-Gal4; UAS-
Vps13EY09640 and inhibition line D42-Gal4; UAS-Vps13-RNAiGD14789 showed the same 
pattern as was observed in the directed dopaminergic neuron-specific experiment. A 
decrease is evident in the overexpression line D42-Gal4; UAS-Vps13EY09640 , and the 
increase in inhibition line D42-Gal4; UAS-Vps13-RNAiGD14789 climbing abilities 
compared to the control D42-Gal4; UAS-lacZ. Inhibition group D42-Gal4;UAS-Vps13-
RNAiHMS01715 and D42-Gal4;UAS-Vps13-RNAiHMS024460 showed no statistically 
meaningful differences compared to the control. 
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Table 6. Statistical analysis of the locomotor ability of D. melanogaster using non-
linear regression curve with directed motorneuron-specific expression with 
inhibition and overexpression of Vps13 
Climbing Analysis 
Genotype Slope (k) SE 95% 
Confidence 
interval (CI) 
P-value Significance 
D42-Gal4;UAS-
lacZ 
0.07113 0.005058 
 
0.06187 to 
0.08149 
N/A N/A 
D42-Gal4;UAS-
Vps13-RNAiHMS01715 
0.06579 
 
0.008606 
 
0.05081 to 
0.08362 
 
0.3449 No 
D42-Gal4;UAS-
Vps13-RNAiHMS02460 
0.06103 
 
0.008154 
 
0.04657 to 
0.07835 
 
0.3818 No 
D42-Gal4;UAS-
Vps13-RNAiGD14789 
0.06450 
 
0.004266 
 
0.05674 to 
0.07314 
<0.0001 Yes 
D42-Gal4; UAS-
Vps13EY09640 
0.04212 
 
0.003587 
 
0.03529 to 
0.04937 
<0.0001 Yes 
 
Figure 13. Overexpression of Vps13 under the control of directed motorneuron- 
specific expression decreases the climbing ability of D. melanogaster while 
inhibition of Vps13 increases it. 
N-value for every critical class group is 50 and p<0.05 considered significant .The 
error bars are made with a CI 95%. 
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Directed neuron-specific expression 
 
 
Longevity Assay 
I compared the longevity of each of the critical class groups with the control group 
Ddc-Gal4; UAS-lacZ using Log-rank statistical analysis. P<0.05 considered significant 
(Figure 14, Table 7). The control group Ddc-Gal4; UAS-lacZ with the N-value of 314 
and the median life span of 64 days has the highest longevity compared to experimental 
groups. Inhibition group Ddc-Gal4; UAS-Vps13-RNAiHMS01715 with the N-value of 311 
and median life span 56 days, inhibition group Ddc-Gal4; UAS-Vps13-RNAiHMS024460 
with the N-value of 331 and a median survival of 54, inhibition group Ddc-Gal4; UAS-
Vps13-RNAiGD14789 with the N-value of 317 and median survival of 62 days, and 
overexpression group Ddc-Gal4; UAS-Vps13EY09640 with the N-value of 320 and median 
survival of 38 days showed a significant decrease compared to control. It is noteworthy 
that the overexpression group Ddc-Gal4; UAS-Vps13EY09640 had the lowest longevity, 
and inhibition group Ddc-Gal4; UAS-Vps13-RNAiGD14789 has the closest longevity to 
the control. 
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Table 7. Log-rank statistical analysis of longevity of flies with directed neuron-
specific expression with inhibition and overexpression of Vps13. 
 
Survivorship Analysis 
Genotype Number 
of Flies 
Median 
Survival 
(Days) 
Chi-square 
Value 
P-value Significance 
Ddc-Gal4;UAS-
lacZ 
314 64 N/A N/A N/A 
Ddc-Gal4;UAS-
Vps13-
RNAiHMS01715 
311 56 100.2 <0.000
1 
Yes 
Ddc-Gal4;UAS-
Vps13-
RNAiHMS02460 
331 54 170.0 <0.000
1 
Yes 
Ddc-Gal4;UAS-
Vps13-
RNAiGD14789 
317 62 11.37 0.0007 Yes 
Ddc-Gal4;UAS-
Vps13EY09640 
320 38 349.7 <0.000
1 
Yes 
 
Figure 14. Inhibition and overexpression of the Vps13 under the control of directed 
neuron-specific expression decreases D. melanogaster longevity. 
P<0.05 onsidered significant. The error bars are made with a CI 95%. 
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Climbing Assay 
I compared the locomotor ability of each critical class group with the control group 
Ddc-Gal4; UAS-lacZ using non-linear regression analysis. N-value for every critical 
class group is 50, and P<0.05 considered significant (Figure 15, Table 8). Inhibition 
group Ddc-Gal4; UAS-Vps13-RNAiGD14789 started with higher climbing scores in the 
first climbing attempt compared to other critical class groups, and its climbing scores 
remained significantly higher than the control throughout the experiment. The rest of 
the experimental groups showed no statistically meaningful change in their locomotor 
abilities compared to control. Yet, overexpression group Ddc-Gal4; UAS-Vps13EY09640 
climbing scores are slightly lower than the control and inhibition group Ddc-Gal4; 
UAS-Vps13-RNAiHMS01715 and Ddc-Gal4; UAS-Vps13-RNAiHMS024460 showed no 
significant difference in their locomotor ability. 
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Table 8. Statistical analysis of the locomotor ability of D. melanogaster using non-
linear regression curve with directed neuron-specific expression with inhibition 
and overexpression of Vps13 
 
Climbing Analysis 
Genotype Slope (k) SE 95% 
Confidence 
interval (CI) 
P-value Significance 
Ddc-Gal4;UAS-
lacZ 
0.06513 0.005815 
 
0.05479 to 
0.07675 
N/A N/A 
Ddc-Gal4;UAS-
Vps13-
RNAiHMS01715 
0.05240 
 
0.008029 
 
0.03816 to 
0.06955 
 
0.1551 No 
Ddc-Gal4;UAS-
Vps13-
RNAiHMS02460 
0.05824 0.005251 
 
0.04833 to 
0.06934 
 
0.6462 No 
Ddc-Gal4;UAS-
Vps13-
RNAiGD14789 
0.06594 
 
0.004680 
 
0.05755 to 
0.07533 
 
<0.0001 Yes 
Ddc-Gal4;UAS-
Vps13EY09640 
0.05956 
 
0.006719 
 
0.04772 to 
0.07271 
0.4484 No 
Figure 15. Inhibition of Vps13 under the control of directed neuron specific 
expression increases D. melanogaster climbing ability. 
N-value for every critical class groups in climbing assay is 50 and p<0.05 considered 
significant. The error bars as made with CI 95%. 
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Directed neuron-specific expression with inhibition of Parkin 
Longevity Assay 
I compared the longevity of each of the lines with the control group using Log-rank 
statistical analysis. P<0.05 considered significant (Figure 16, Table 9). In this 
experiment, I determined the effect of neuron-specific inhibition and overexpression of 
Vps13 along with the inhibition of Parkin. The control line Ddc-Gal4;UAS-parkin-
RNAi; UAS-lacZ showed an N-value of 328 and median survival of 60 days. This 
number was 64 days in control group Ddc-Gal4; UAS-lacZ. Inhibition lines Ddc-
Gal4;UAS-parkin-RNAi;UAS-Vps13-RNAiHMS01715, with N-value 278 of and median 
survival of 54 days, Ddc-Gal4; UAS-parkin-RNAi; UAS-Vps13-RNAiHMS024460 with N-
value of 296 and median survival of 54 days, and overexpression line Ddc-Gal4; UAS-
parkin-RNAi; UAS-Vps13EY09640 with N-value of 304 and a median survival of 50 days 
showed a significant decrease in their longevity compared to the control Ddc-
Gal4;UAS-parkin-RNAi; UAS-lacZ. Inhibition line Ddc-Gal4; UAS-parkin-RNAi; 
UAS-Vps13-RNAiGD14789 had no substantial change in its longevity. Like our results in 
the directed neuron-specific experiment, control Ddc-Gal4;UAS-parkin-RNAi; UAS-
lacZ had the best median survival score, inhibition group Ddc-Gal4; UAS-parkin-RNAi; 
UAS-Vps13-RNAiGD14789 had the closest scores to the control Ddc-Gal4;UAS-parkin-
RNAi;UAS-lacZ, and overexpression line Ddc-Gal4; UAS-parkin-RNAi; UAS-
Vps13EY09640 had the lowest scores. The overexpression line Ddc-Gal4; UAS-parkin-
RNAi; UAS-Vps13EY09640 showed an improvement in its longevity compared to the 
directed neuron-specific overexpression line Ddc-Gal4;UAS-Vps13EY09640. 
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Table 9. Log-rank statistical analysis of longevity of flies with directed neuron-
specific expression with inhibition of Parkin, along with inhibition and 
overexpression of Vps13. 
 
 
Survivorship Analysis 
Genotype Number of 
Flies 
Median 
Survival 
(Days) 
Chi-
square 
Value 
P-value Significance 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
lacZ 
328 60 N/A N/A N/A 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiHMS01715 
278 54 104.8 <0.0001 
 
Yes 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiHMS02460 
296 54 96.72 <0.0001 Yes 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiGD14789 
296 58 2.106 0.1468 
 
No 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13EY09640 
304 50 103.8 <0.0001 Yes 
Figure 16.  Directed neuron specific expression with inhibition of Parkin 
improves the effect of inhibition and overexpression of Vps13 on Drosophila 
melanogaster longevity. 
The error bars as made with CI 95%. P<0.05 considered significant. 
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Climbing Assay 
I compared the locomotor ability of each line with the control group using non-linear 
regression analysis. N-value for every line is 50, and P<0.05 considered significant 
(Figure 17, Table 10). The inhibition line Ddc-Gal4; UAS-parkin-RNAi; UAS-Vps13-
RNAiGD14789 started with a better quality of climbing compared to all other groups and 
had a better locomotor ability compared to the control. Climbing ability decreased in 
the inhibition lines Ddc-Gal4;UAS-parkin-RNAi;UAS-Vps13-RNAiHMS01715 and Ddc-
Gal4; UAS-parkin-RNAi; UAS-Vps13-RNAiHMS024460. Surprisingly overexpression line 
Ddc-Gal4; UAS-parkin-RNAi; UAS-Vps13EY09640 had a significant increase in the 
locomotor ability compared to control while overexpression line Ddc-Gal4;UAS-
Vps13EY09640 showed no substantial climbing change with its relative control group .  
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Table 10. Statistical analysis of the locomotor ability of D. melanogaster using 
non-linear regression curve with directed neuron-specific expression with 
inhibition of Parkin, along with inhibition and overexpression of Vps13 
 
Climbing Analysis 
Genotype Slope (k) SE 95% 
Confidence 
interval 
(CI) 
P-value Significance 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
lacZ 
0.03987 
 
0.001577 
 
0.03670 to 
0.04316 
 
N/A N/A 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiHMS01715 
0.03999 
 
0.003317 0.03377 to 
0.04664 
 
0.0267 Yes 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiHMS02460 
0.03630 
 
0.003139 
 
0.03044 to 
0.04251 
 
0.0030 Yes 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13-RNAiGD14789 
0.06512 
 
0.004043 
 
0.05784 to 
0.07318 
 
<0.0001 Yes 
Ddc-Gal4;UAS-
Parkin-RNAi;UAS-
Vps13EY09640 
0.02924 
 
0.001871 
 
0.02540 to 
0.03328 
 
<0.0001 Yes 
 
Figure 17.  Directed neuron specific expression with inhibition of Parkin 
improves the effect of overexpression of Vps13 in D. melanogaster’s climbing 
ability. N-value is 50.The error bars as made with CI 95%. P<0.05 considered 
significant. 
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Summary of Results 
 
Bioinformatic analysis of Vps13 in D. melanogaster and Vps13C in Homo sapiens 
showed high levels of conservation in their domains (Figure18). The presence of the 
ATG-C domain, which was highly conserved among vertebrates in invertebrates, 
interested me in investigating the role of VPS13C in autophagy pathways. ATG2A is 
an autophagy-related protein containing Chroein-N and ATG-C domains that regulates 
autophagy and lipid droplet morphology in mammalian cells (Velikkakath et al., 2012). 
Despite sharing the same domains with ATG2A, VPS13C does not seem to be involved 
in the autophagy pathways. However, VPS13A, the closest member of the VPS13 
family to VPS13C, has been reported to be involved in autophagy regulation (Muñoz-
Braceras, Calvo and Escalante, 2015; Yang et al., 2016). Please see figure 3 for multiple 
alignments of ATG2A and human VPS13C protein and figure 18 for the schematic view 
of existing domains in these proteins. 
 
  
Figure 18.  Comparison of Drosophila melanogaster Vps13 protein (A) and Homo 
sapiens VPS13C protein (B) with conserved domains. Highlighted are Chorein-N 
(Green), VPS13 (Red), VPS13 mid rpt (Blue), SHR-BD (Yellow), VPS13C (Purple), 
ATG-C (Orange), DUF1162 (Black). This image was generated with draw.io. 
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Eye analysis showed a distinct bristle void in D. melanogaster’s eye when Vps13 
was overexpressed, while the bristle number increased when Vps13 was inhibited 
(Figure 19; Table 11). 
Table 11. Summary of eye analysis.   Arrows pointing up, indicate an increase and 
arrows pointing down, indicate a decrease. 
Neurodevelopment Analysis 
Genes Ommatidia 
Number 
Bristle 
Number 
Bristle 
Void Area Inhibition Lines 
GMR-Gal4;UAS- Vps13-RNAiHMS01715 +  +  +  
GMR-Gal4;UAS- Vps13-RNAiHMS02460 +  +  +  
GMR-Gal4;UAS- Vps13-RNAiGD14789 - +  +  
Overexpression Line 
GMR-Gal4;UAS-Vps13EY09640 - +  +  
  
Figure 19. SEM image showing the phenotypic impact of overexpresing Vps13 in 
D. melanogaster eye.  
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Ageing and Climbing Assay 
I analyzed the impact of inhibition and overexpression of Vps13 in some specific 
tissues, on D. melanogaster’s ageing and climbing ability. Table 12 is a summary of my 
findings. 
 
Table 12. Summary of results in survivorship and climbing abilities of                
D. melanogaster. Arrows pointing up, indicate an increase and arrows pointing down, 
indicate a decrease ‘A’ stands for Aging and ‘C’ stands for climbing. 
  
Responder lines Transgenic Lines 
Inhibition Lines 
 
Th-Gal4 D42-Gal4 Ddc-Gal4 Ddc-Gal4;UAS-Parkin-
RNAi 
A C A C A C A C 
GMR-Gal4;UAS- 
Vps13-RNAiHMS01715 
+  +  +  - +  - +  +  
GMR-Gal4;UAS- 
Vps13-RNAiHMS02460 
+  - - - +  - +  +  
GMR-Gal4;UAS- 
Vps13-RNAiGD14789 
+  +  +  +  +  +  - +  
Overexpression Line 
GMR-Gal4;UAS-
Vps13EY09640 
+  +  +  +  +  - +  +  
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Discussion 
Parkinson Disease (PD) is the most common movement disorder, a result of the loss 
of dopaminergic neurons in the substantia nigra pars compacta in the midbrain (Bilen 
and Bonini, 2005). With an incidence of 1% among 65-year-olds, the prevalence of PD 
increases with age (Farrer, 2006). This neurodegenerative disease is clinically 
characterized by the symptoms of resting tremor, rigidity, and bradykinesia. A projected 
increase in the average age of the population in the next decade emphasizes the 
importance of this study.  There is no absolute cure for this debilitating disease, and 
dopamine replacement treatments alleviate only some of the symptoms moreover the 
beneficial effects are gradually lost, and intolerable side effects can be produced (Guo, 
2012). Some of the risk factors, including genetic and environmental risk factors, have 
been identified, yet there is much to discover before a thorough understanding of PD is 
achieved.   
Disruption in mitochondrial function, especially in the pathways related to the 
mitochondrial autophagy (mitophagy), and mitochondrial fission and fusion, can result 
in the occurrence of PD. For example, one of the genetic pathways involved in the 
mitochondrial integrity and maintenance through proper fission and fusion is the Pink1-
parkin pathway, in which the Pink1 protein kinase positively regulates the parkin 
ubiquitin ligase to “sense” mitochondrial damage, and recruits the damaged 
mitochondria into a quality-control system for further actions. Mutations in these genes  
and those that act with them can result in PD (Guo, 2012). Only 5 to 10 percent of the 
PD cases are known to be genetic-based. However, scientists are discovering more 
about inherited forms of PD with an emphasis on the involved pathways. In 2017 whole-
exome sequencing (WES) identified VPS13C as a PD candidate gene (Jansen et al., 
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2017). In this set of studies, I studied the VPS13C orthologue, Vps13, in D. 
melanogaster as a model organism. 
VPS13C  in humans is associated with transport through the endomembrane system, 
from the Golgi Body to the endosomes (Saxena et al., 2010), lipid transportation 
between mitochondria and other organelles (Kumar et al., 2018), adipogenesis (Yang 
et al., 2016),  early impairment of blood glucose homeostasis (Windholz J et al., 2011), 
mitochondrion organization, and mitophagy (Lesage et al., 2016). The molecular 
function of Vps13 in D. melanogaster is still unknown. However, studies show that 
Vps13 is involved in vacuolar protein targeting, protein metabolic process, lysosomal 
degradation pathways, and protein homeostasis maintenance in the brain of adult D. 
melanogaster (Vonk et al., 2017). In this study, I assessed the impact of inhibition and 
overexpression of the Vps13 upon survivorship and locomotor ability of flies.  
Bioinformatic analysis shows that the Vps13 protein is highly conserved among both 
vertebrates and invertebrates (Figure 2). The protein, in vertebrates and invertebrates, 
contain shared domains (Figure 18) including an amino-terminal region of Chorein 
(Chorein N), a Vacuolar-sorting associated protein 13 (VPS13) domain, a SHR-binding 
domain (SHR-BD), Vacuolar-sorting associated protein 13 repeating coiled regions 
(VPS13 mid rpt), DUF1162, a Vacuolar sorting-associated 13 protein carboxy-terminal 
(VPS13C) and an Autophagy- related protein C-terminal domain (ATG C). This 
information allowed me to pursue to the next level of my experiment, which was the 
analysis of the effect of Vps13 on the development of D. melanogaster eye units. 
Eye analysis, experimentation meant to provide an assessment of the influence of 
applied gene manipulation of Vps13 upon neurodevelopment, revealed the presence of 
a 33.3% area void of bristles when Vps13 was overexpressed in the developing D. 
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melanogaster eye (Figure 19). This means that overexpression of Vps13 interfered with 
the process of neurodevelopment in a subtle but clear manner (Kramer and Staveley, 
2003). Furthermore, inhibition of Vps13 consistently influenced neurodevelopment of 
the D. melanogaster eye and resulted in a decrease in the area of bristle void.  
These findings in the eye analysis combined with collected information in 
bioinformatics encouraged us to analyze the impact of inhibition and overexpression of 
Vps13 in different tissues on the survival and locomotor ability of D. melanogaster. 
Please see table 12 for the summary of ageing and climbing assays. Flies expressing the 
UAS-Vps13-RNAiHMS01715, construct under the control of neural-specific Gal4 drivers 
showed a decrease in their longevity in all cases, and showed a decrease or no 
differences in their climbing ability. It is noteworthy that the only noticeable impact of 
UAS-Vps13-RNAiHMS01715 when it was expressed in the motorneuron tissues was on 
longevity. Inhibition of Vps13 via expression of UAS- Vps13-RNAiHMS02460, did not have 
a significant impact on the longevity or the climbing ability of flies. On the other hand, 
Inhibition of Vps13 via UAS- Vps13-RNAiGD14789, mostly improved survival and 
climbing ability of flies. Overexpression of the Vps13 via UAS-Vps13EY09640 in  D. 
melanogaster mainly reduced their survival and longevity. 
In humans, VPS13C is associated with rapid progressing early-onset parkinsonism 
with the presence of widely distributed Lewy bodies, which affects the survival of 
dopaminergic neurons (Lesage et al., 2016). Loss of VPS13C function increases the 
vulnerability of mitochondria to stress, which activates the Pink1/parkin-dependent 
mitochondrial quality control pathways and exacerbates Pink1/parkin response to 
mitochondrial depolarization. Mitochondrial depolarization partially redistributes 
VPS13C from mitochondrial surface to the cytosol space without significantly affecting 
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the transcription level of VPS13C.  Pink1 and Parkin are involved in a pathway that 
transports damaged mitochondria directly to lysosomes in response to mitochondrial 
stress. Based on the VPS13C protein localization within mitochondria and its relocation 
to the cytosol in response to mitochondrial damage, VPS13C might be involved in this 
process as well. Pink1, park2, and VPS13C are engaged in a regulatory loop in which 
Pink1 silencing is associated with downregulation of transcription levels of VPS13C 
while overexpression of Pink1 upregulates VPS13C transcription levels. Silencing 
VPS13C increases the Pink1/parkin-mediated mitophagy levels (Lesage et al., 2016) 
and as explained earlier mitophagy regulation can affect cellular longevity. 
A study in 2018 suggested that VPS13C and VPS13A transport lipids between the 
endoplasmic reticulum (ER) and other organelles (Kumar et al., 2018). They found that 
mutation in VPS13C and VPS13A vitiates the lipid homeostasis of membranes in 
neurological disorders. Mitochondria use exogenous precursors to produce most of their 
lipids. These precursors are particularly exported from ER to mitochondria, and because 
the membranes of these two organelles are not directly connected to each other by 
membrane traffic, the presence of a protein-mediated transport becomes particularly 
necessary for these exchanges. Kumar et al., 2018 hypothesized that Vps13 is the 
protein that mediates the transfer of lipids among vacuoles and other membranes and 
that it possibly provides an alternative path through vacuoles for transferring lipids from 
ER to mitochondria. Some studies showed that spontaneous gain-of-function mutations 
in Vps13 gene in yeast could rescue growth defects that were originally created by 
mutations in ER-mitochondria encounter structure (ERMES), and lack of both Vps13 
and ERMES is lethal (Lang et al., 2015); moreover, mutant yeast that lacked either ERMES 
or Vps13 showed defects in the integrity of their mitochondrial membrane (Park et al., 2016) 
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which  are consistent with their hypothesis. Earlier, I explained how LOF mutation in 
VPS13C resulted in mitochondrial dysfunction (Lesage et al., 2016).  However, 
VPS13C proteins were not present at the mitochondrial contact sites, suggesting that 
the observed dysfunction might have been as a result of an abnormality that indirectly 
had influenced the intracellular lipid transport (Kumar et al., 2018). They found that 
VPS13A proteins were anchored at the mitochondrial contact sites while VPS13C were 
localized on the late endosomes/lysosomes, and both VPS13A and VPS13C were 
attached on the lipid droplets through their N-terminals. Their observations showed that 
overexpression of VPS13A and VPS13C results in an expansion in the contacts between 
organelles. Our observation in the eye analysis followed by survival and longevity 
assays showed that in most cases, overexpression of Vps13 reduces robustness in flies 
while inhibition of Vps13 increased measures of climbing and longevity (Table 13). 
These observations could be a result of using different techniques for inhibition and 
overexpression of this gene. VPS13 LOF in the Lesage study was through mutation 
while I used siRNA coupled with UAS-Gal4 system to inhibit the translation of the gene 
in a specific tissue. Furthermore, overexpression of VPS13C increased the contacts 
between organelles, however, the increase in the amount of a protein can as well be 
cytotoxic and lethal for cells. It should also be noted that most of the studies on VPS13C 
were done on Sacaromyses cervisiae which has less similarity to human VPS13C in 
terms of its protein sequence compared to D. melanogaster. 
With the present study, I successfully characterized and identified the D. 
melanogaster homologue of VPS13C. Although there remains insufficient information 
about the exact function of this gene, its high level of conservation among vertebrates 
and invertebrates suggests the importance of this gene. Furthermore, consistent 
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evidence of the presence of Vps13 in mitochondrial regulatory pathways of mitophagy 
underscores its link to Parkinson disease. Further analyses should be carried out at the 
cellular and molecular levels, such as microarray and PCR analyses, primarily due to 
the involvement of Vps13 in protein-mediated lipid transportation and mitophagy. As 
well, further research into the interaction of Vps13 with other genes such as Pink1, 
parkin, Rab7, and FBXO7 may provide valuable insight into the role of Vps13 in the 
etiology of PD . 
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